BCRX — BIOCRYST PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 882796 ·
Last close
$9.68
Market Cap
$2.47B
52W High
$11.22
52W Low
$8.06
ADV30
3,296,342
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 218,250,000 | 214,410,000 | 98,465,000 | 78,395,000 | 557,851,000 | 154,972,000 | 1,012,140,000 |
| Mar 2026 | 156,413,000 | 151,036,000 | -701,598,000 | -721,812,000 | 465,052,000 | 171,591,000 | 1,018,895,000 |
| Dec 2025 | 406,555,000 | 397,033,000 | 260,385,000 | 245,845,000 | 514,158,000 | 89,736,000 | 633,311,000 |
| Sep 2025 | 159,395,000 | 157,208,000 | 29,591,000 | 12,899,000 | 446,424,000 | 84,078,000 | 834,313,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$313,095,000
Investing CF
$-309,437,000
Financing CF
$62,092,000
CapEx
$-2,728,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.78
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,227,991,000
Inventory
$5,985,000
Receivables
$109,272,000
ST Investments
$66,809,000
EBIT TTM
$-379,018,000
Pretax Income TTM
$-454,175,000
Interest Exp TTM
$75,157,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$940,612,992
EBITDA
$433,647,008
Free Cash Flow
$324,266,752
Enterprise Value
$2,957,651,712
Total Cash
$352,572,992
Total Debt
$836,644,992
Shares Out
255,535,105
Trailing EPS
$-1.40
Book Value
$-1.78
ROE
—
ROA
52.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 874,837,000 | 340,989,000 | 263,861,000 | 514,158,000 | 633,311,000 | — | 347,369,000 |
| Dec 2024 | 450,712,000 | -2,543,000 | -88,881,000 | 490,420,000 | 966,354,000 | — | -52,020,000 |
| Dec 2023 | 331,412,000 | -103,709,000 | -226,539,000 | 516,960,000 | 972,488,000 | — | -95,141,000 |
| Dec 2022 | 270,827,000 | -148,435,000 | -247,116,000 | 550,000,000 | 844,597,000 | — | -161,850,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.94
Max Pain — expiry 2026-09-18
max pain strike: $10.00 · spot: $9.70 · call oi: 50,728 · put oi: 8,760
Expected Move to 2026-09-18:
±$1.40
(14.43%) —
implied range
$8.30 –
$11.10
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MEOBF | MESOBLAST LTD | $2.45B | $1.89 | — |
| KOD | Kodiak Sciences Inc. | $2.34B | $37.22 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.18B | $46.67 | — |
| VCEL | Vericel Corp | $2.17B | $42.30 | — |
| MESO | MESOBLAST LTD | $2.16B | $16.64 | — |
News headlines (Yahoo Finance, 1h cache)
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
2026-08-25 11:01 · Yahoo
Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update?
2026-08-13 09:10 · Yahoo
BioCryst (BCRX) Q2 2026 Earnings Call Transcript
2026-08-12 17:29 · Yahoo
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
2026-08-12 13:55 · Yahoo
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options
2026-08-11 14:43 · Yahoo
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
2026-08-11 13:20 · Yahoo
BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
2026-08-05 21:05 · Yahoo
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation
2026-08-05 14:39 · Yahoo
BioCryst to Report Second Quarter 2026 Financial Results on August 5
2026-07-22 11:00 · Yahoo
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
2026-07-15 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.